
Dengue virus (DENV) is classically regarded as a non-neurotropic systemic pathogen, yet severe neurological complications, most notably meningoencephalitis, are increasingly recognized. This review synthesizes the available evidence on the molecular determinants of DENV neuroinvasion and central nervous system (CNS) injury, indicating which steps are established and which remain hypothetical. Crossing of the blood–brain barrier is thought to involve secreted non-structural protein 1 (NS1), which degrades the endothelial glycocalyx, and together with matrix metalloproteinase-9 impairs endothelial junctions (the role of TLR4 is disputed), as well as monocyte-mediated trans-endothelial migration. Disease severity may be shaped by antibody-dependent enhancement (ADE) during secondary heterologous infection through extrinsic (enhanced viral entry) and intrinsic (suppressed antiviral signaling) mechanisms documented in peripheral myeloid cells and proposed here, by extrapolation, to operate in microglia, possibly counterbalanced by natural killer cell-mediated cytotoxicity. Elevated cerebrospinal fluid IL-6 and TNF-α indicate neuroinflammation; by extrapolation from other flaviviruses, microglial activation and impaired astrocytic glutamate clearance may converge on NMDA receptor-mediated excitotoxicity and neuronal apoptosis, a step not directly examined in dengue. As much of this model rests on peripheral, in vitro, animal, or other-flavivirus data, CNS-focused mechanistic studies are needed.
Neurodegenerative diseases are biologically heterogeneous disorders in which pathological protein accumulation, axonal injury, synaptic dysfunction, glial activation, and genetic variation evolve before conventional clinical phenotypes become fully established. This review examines these disorders through a molecular-pathology framework that links biomarker biology to specimen type, pre-analytical handling, analytical platform, clinical interpretation, and therapeutic stratification. Established fluid biomarkers, including amyloid-β42/40, phosphorylated tau (p-tau217, p-tau181, and p-tau231), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), are evaluated alongside disease-specific assays for α-synuclein and emerging TDP-43, synaptic, and endo-lysosomal markers. We critically compare mass spectrometry, single-molecule array, proximity extension, nucleic-acid-linked immunoassay, automated immunoassay, and seed-amplification approaches, emphasizing analytical sensitivity, multiplexing, standardization, and readiness for clinical deployment. The review then considers how proteomics, transcriptomic signals, genetic information, imaging, digital phenotypes, and machine learning can be integrated without obscuring biological interpretability. Across biomarker classes, the major translational bottleneck is no longer analytical detection alone; it is demonstration that a measured signal is biologically attributable to central nervous system pathology, reproducible across platforms and populations, and useful for a defined clinical decision. We therefore propose a pathology-to-clinic framework organized around four linked requirements: analytical validity, biological validity, clinical validity, and clinical utility. This framework prioritizes standardized pre-analytical workflows, orthogonal confirmation, externally validated thresholds, diverse population testing, and prospective evidence that biomarker-guided decisions improve patient management. The resulting approach positions molecular pathology, not algorithmic prediction alone, as the interpretive bridge between multi-omics discovery and precision diagnosis.
Background: Cannabidiol (CBD), isolated from hemp (Cannabis sativa or Cannabis indica), is receiving increasing attention for its therapeutic potential in various diseases, including viral infections. CBD has been reported to alter lateral membrane diffusion and cholesterol accessibility. However, it remains unclear which signaling pathways are affected by CBD treatment. Here, we sought to determine the effect of CBD treatment on human cell lines and primary human cells. Methods: We performed a bioinformatics analysis to identify differentially expressed genes (DEGs) in published RNA-seq datasets of CBD-treated cells, including A549, THP-1, normal human epidermal keratinocytes (NHEK), monocyte-derived dendritic cells (DC), and monocyte-derived macrophages (MDM). We then validate the A549, THP-1, and MDM sequencing data by RT-qPCR. Results: Comparative transcriptional analysis across five CBD-treated cell types identified 22 genes shared across all cell types, 138 among four, and 695 among three; these genes were enriched in endoplasmic reticulum (ER) stress, lipid metabolism, and cholesterol metabolism pathways. Transcription factor enrichment analysis identified ATF4, ATF6, XBP1, SREBF1, and SREBF2, which encode key regulators of the ER stress response and cholesterol metabolism. Conclusions: These results highlight a role for CBD in regulating the expression of transcription factors that control genes involved in ER stress, lipid, and cholesterol metabolism. Consequently, CBD treatment modulates gene expression programs in a context-dependent manner and may be associated with lipotoxic stress through dysregulation of ER stress signaling pathways.
Background: Fat embolism is a clinically significant condition characterized by systemic fat dissemination, often leading to life-threatening complications. Traditionally associated with trauma, FE is increasingly recognized in diverse contexts, including orthopedic and aesthetic procedures. Despite extensive investigation, essential gaps remain regarding its pathophysiology, diagnostic approaches, and targeted treatments. Methods: Following PRISMA guidelines, we systematically reviewed experimental studies on FE published in PubMed and Embase from Jan 2000 to May 2026. Eligible studies investigated (1) models of fat embolism pathophysiology, (2) orthopedic or aesthetic procedure–related fat embolism, and (3) diagnostic or management strategies. Human studies and inaccessible full texts were excluded. Of the 3395 records identified, 100 met the inclusion criteria after duplicate removal (n = 744) and screening (n = 2651). Data extraction was conducted independently by four reviewers, with disagreements resolved by consensus. Results: One hundred experimental studies were included. Findings demonstrated that fat embolism develops through two mechanisms: vascular obstruction and systemic inflammation. Orthopedic procedures and aesthetic interventions significantly increase the risk of embolism. Advanced imaging modalities, such as dual-energy CT, and biomarkers, particularly IL-6, improved detection. Targeted therapies, including NLRP3 inflammasome inhibitors and renin–angiotensin modulators, reduced lung injury and improved survival in severe cases. Discussion: This review integrates mechanistic insights into the biphasic injury patterns and organ-specific vulnerabilities of fat embolism. Preventive procedural strategies may reduce risk, while novel diagnostics and targeted pharmacological approaches show translational potential. Limitations include methodological heterogeneity across studies.
Background/Objectives: O-GlcNAcylation is a post-translational modification affecting diverse cell functions, including transcriptional regulation. Aberrant levels of protein O-GlcNAcylation have been observed in neurodegenerative and cardiovascular diseases. We have previously demonstrated that systemic elevation of protein O-GlcNAcylation significantly impacted the brain transcriptome. Method: In the current study, we investigated the impact of acute inhibition of O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modification from proteins using a pharmacological inhibitor, on the heart transcriptome. Results: RNA sequencing analysis detected differentially expressed genes in response to treatment with thiamet G (TG), a selective inhibitor of OGA. Pathway enrichment analysis showed oxidative phosphorylation as the top upregulated pathway, while the top downregulated pathway was related to ECM–receptor interactions. As the O-GlcNAcylation pathway is prevalent in many tissues, we hypothesized that systemic pharmacological inhibition of OGA would have a similar impact on gene regulation in the heart and brain. To test this, we compared the TG-dependent changes in the heart transcriptomes with our findings in the brain. We found overlapping differentially expressed genes associated with extracellular matrix remodeling and Alzheimer’s disease-related pathways, while metabolism, including the oxidative phosphorylation pathways, is unique to the heart. Conclusions: These studies provide new insights into the impact of acute pharmacological modulation of OGA on gene expression across the brain and heart.